



BioSyent Inc.

Q4/FY 2024 Results

MARCH 13, 2025

PRESENTED BY: RENÉ GOEHRUM
PRESIDENT AND CEO



DISCLAIMER

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.

By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

All values in CAD unless otherwise indicated.





RepaGyn®

Cathejell®

inofolic®^{MD}



^cTibella®

Tibelia Global




Proktis-M®

Combogesic®^{MD}




Sales, EBITDA and NIAT

Quarter ended December 31st (Q4)



Sales, EBITDA and NIAT

Year ended December 31st (FY)



Q4/FY 2024 Sales Summary (\$)


	Q4 '24 Sales (\$)	Q4 '24 vs. Q4 '23 (%)	FY '24 Sales (\$)	FY '24 vs. FY '23 (%)
Canadian Pharma (\$)	\$8,546k	+7%	\$32,931k	+11%
Cathejell®		+4%		+3%
Combogesic®		+39%		+66%
FeraMAX® Pd		+7%		+10%
Gelclair®		+26%		+357%
Inofolic®		+92%		+328%
RepaGyn®		(19%)		+4%
Tibella® (Canada)		+41%		+35%
International Pharma (\$)	\$177k	+223%	\$930k	(11%)
Legacy (\$)	\$74k	(68%)	\$1,170k	+18%
Total Company (\$)	\$8,797k	+6%	\$35,031k	+11%

Fully Diluted Earnings per Share

58 Consecutive Profitable Quarters to Q4 2024

Quarter	NIAT	Diluted EPS
Q4 2024	\$1,613,194	\$0.14
Q3 2024	\$2,307,894	\$0.20
Q2 2024	\$1,580,289	\$0.13
Q1 2024	\$1,768,727	\$0.15
Q4 2023	\$1,450,791	\$0.12
Q3 2023	\$2,350,900	\$0.20
Q2 2023	\$1,483,190	\$0.12
Q1 2023	\$1,175,246	\$0.10

15 Years of Profitable Growth (and Counting!)



f/d shares: 14,336,194 11,596,399

2024 Highlights

- Feb 2024: BioSyent named to 2024 TSX Venture 50



- Mar/Jun/Sep/Dec 2024: Quarterly dividends of \$0.045 paid (+12.5% increase vs. 2023)



- Apr 2024: FeraMAX[®] named #1 recommended iron supplement in Canada for ninth consecutive year



- Apr 2024: Extension of RepaGyn[®] and Proktis-M[®] Agreement to 2032



2024 Highlights (Continued)

- Jun 2024: In-licensing of new endocrinology product for Canada



- Sept 2024: Acquisition of Tibelia[®] / Tibella[®] (tibolone) global assets



- Jan – Dec 2024: 492,300 shares repurchased and cancelled under NCIB



- Dec 2024: NCIB Renewed for a further 12 months – 690,000 maximum share purchase limit

2025 YTD Highlights

- Jan 2025: Declaration of Q1 2025 dividend of \$0.05/share (+11% increase vs. 2024)



- Jan/Feb 2025: First Tibelia® Global shipments made by BioSyent
~\$0.8 million in incremental revenue YTD 2025

Tibelia Global

- YTD 2025: 18,400 shares repurchased and cancelled under NCIB



Trade and Tariffs

- USA-Canada Tariffs / Counter-Tariffs
- Impact of Tariffs on Global Trade and Economies
- Uncertainty





Growth Drivers

New endocrinology asset



FeraMAX[®] Pd Platform – Life Cycle Strategy



Tibela[®] / Tibella[®] (tibolone) - HRT agent for menopause therapy



Management of symptoms of PCOS




Oncology supportive care product for Oral Mucositis



Acquisition and in-licensing – ongoing



Cash Balance & Return on Equity (“RoE”)



- Zero Debt
- 2024 Cash from Operations of **\$8.7M**
- 2024 NCIB share buybacks: **\$5.2 M**
- 2024 Dividends of **\$2.1M**
- Dec 31/24 Working Capital of **\$19.1M**
- Execution of strategy drives 2024 RoE of **21%**

Innovations, Product Launches and Acquisitions

Tibella®

Jul 2020



FeraMAX® Pd

Oct 2020



FeraMAX® Pd Therapeutic 150

Nov 2020



Combogesic®

Dec 2020

Combogesic®

FeraMAX® Pd Powder 15

Oct 2021



FeraMAX® Pd Maintenance 45

Mar 2023



Inofolic®

Aug 2023

inofolic®

Gelclair®

Nov 2023



Tibelia® Global

Sep 2024


Tibelia Global



Capital Allocation linked to Strategy

First use of capital is to generate revenue growth & portfolio diversification.

- 7 new product launches in Canada since July 2020
- Tibelia[®] / Tibella[®] (tibolone) Global Acquisition in Sept 2024



Excess capital may also be returned to shareholders:

- Quarterly Dividends – Q4'22 – Q1'25 = \$ 5.1 M to date (incl. Mar '25)
- 3.1 million shares repurchased via NCIB since 2018 = \$22.6 M to date
- Reduced fully diluted shares by 21% = \$27.7 M

Stock Information

As at March 11, 2025

Exchange & Trading Symbol	TSXV: RX
March 11, 2025 Closing Stock Price (CAD) (TSXV):	\$10.80
52 Week Hi/Low (TSXV):	\$12.13 / \$8.24
Issued Common Shares:	11,465,816
Treasury – RSU Shares in Trust	(202,199)
Outstanding Common Shares:	11,263,617
Options Outstanding	124,282
RSUs Outstanding	208,500
Fully Diluted Common Shares:	11,596,399
P/E Ratio :	17.23
EV/EBITDA :	10.23

RSUs funded with shares purchased in open market



- ✓ PROFITABLE.
- ✓ WELL CAPITALIZED.
- ✓ GROWTH ASSETS.
- ✓ FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN.

